Mechanism

A long-acting amylin receptor agonist (amylin analog). In research, amylin signaling is associated with slowed gastric emptying and increased satiety, complementary to GLP-1 pathways.

Research summary

Investigational and not FDA-approved as a standalone therapy. It has been studied for weight management, including in combination with semaglutide (the combination studied under the name CagriSema). Phase 2 and phase 3 evaluation has been reported in the literature.

Reported side effects

Gastrointestinal effects (nausea, vomiting) are the most commonly reported in trials, consistent with the amylin/incretin class. The full safety profile continues to be characterized in ongoing trials.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Cagrilintide and CagriSema weight-management trials · peer-reviewed clinical trials (e.g. The Lancet) (2023)search PubMed for cagrilintide
Amylin analog development reviews · peer-reviewed review articles (2023)investigational; not FDA-approved as standalone

TrackPep adalah aplikasi pencatatan. Aplikasi ini merekam apa yang Anda catat dan tidak pernah merekomendasikan atau menghitung jumlahnya.